Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
BACKGROUND
Primary treatment of endometrial cancer with progestogens is reserved for adjuvant or palliative treatment, although with unproven efficacy.


METHODS
We present a case of early endometrial cancer where a combination of oral progestogens and levonorgestrel releasing intrauterine system (Mirena) was used as a primary treatment, as the standard surgical treatment was deemed to carry an unacceptable mortality risk.


CONCLUSIONS
Our treatment has resulted in reversion of the cancerous endometrial histological changes. This is encouraging, but obviously more cases and lengthier follow-up time are required in order to obtain more valid conclusions.
Giannopoulos
Theodoros
T
Department of Gynaecological Oncology, Royal Surrey County Hospital, Guildford, UK. tgiuk@yahoo.com
Butler-Manuel
Simon
S
Tailor
Anil
A
D000284:Administration, Oral; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007434:Intrauterine Devices; D016912:Levonorgestrel / Q000008:administration & dosage*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*
D018931:Antineoplastic Agents, Hormonal; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate